The news release Monday morning grabbed my attention:
�Study finds wide gap in quality ofBRCA1/2
variant classification between Myriad Genetics and a common public database.�Myriad Genetics had been exclusively providing the tests, for $3000+ a pop for full
BRCA gene sequencing, for 17 years before the Supreme Court invalidated
key gene patents back in 2013. Since the ruling a dozen or so competitors have been offering the tests for much lower prices. Meanwhile, Myriad has amassed a far deeper database than anyone else, having been in the business so much longer. And it�s proprietary.
Published on April 22, 2017 21:00